HealthRight 360, one of three nonprofits working with The City to open drug resource centers in San Francisco neighborhoods hardest hit by the opioid crisis, says it has enough funding to operate an overdose prevention site.
Major companies committed to joining Medicare drug price negotiations; Boehringer Ingelheim introduced a low-cost version of its adalimumab biosimilar; schools begin to stock naloxone amid rising opioid deaths among young people.